1. Home
  2. ELWS vs MRKR Comparison

ELWS vs MRKR Comparison

Compare ELWS & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Earlyworks Co. Ltd.

ELWS

Earlyworks Co. Ltd.

BUY

Current Price

$7.10

Market Cap

19.8M

Sector

N/A

ML Signal

BUY

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$2.10

Market Cap

16.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELWS
MRKR
Founded
2018
N/A
Country
Japan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.8M
16.6M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
ELWS
MRKR
Price
$7.10
$2.10
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$10.17
AVG Volume (30 Days)
26.6K
547.5K
Earning Date
03-02-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,083,071.00
$4,694,988.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
145.52
N/A
52 Week Low
$1.64
$0.81
52 Week High
$10.50
$4.07

Technical Indicators

Market Signals
Indicator
ELWS
MRKR
Relative Strength Index (RSI) 64.84 63.59
Support Level $5.40 $1.93
Resistance Level $6.34 $2.29
Average True Range (ATR) 0.81 0.26
MACD 0.09 0.01
Stochastic Oscillator 90.00 60.92

Price Performance

Historical Comparison
ELWS
MRKR

About ELWS Earlyworks Co. Ltd.

Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Share on Social Networks: